The city of Nashville, Tennessee, currently has 295 active clinical trials seeking participants for Cancer research studies.
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: Identify the recommended dose of AC699 that can be given safely to participants Evaluate the safety profile of AC699 Evaluate the pharmacokinetics of AC699 Evaluate the effectiveness of AC699
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 01, Nashville, Tennessee
Conditions: Breast Cancer
Register for Updates
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131
Recruiting
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
NCT04982926
Recruiting
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Register for Updates
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630
Recruiting
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee +1 locations
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
Recruiting
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: Learn how well the combination of tucatinib and Doxil works Learn more about the side effects of the combination of tucatinib and Doxil
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee +1 locations
Conditions: Breast Cancer
Register for Updates
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
NCT05098132
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Sarah Cannon Research Institute - Nashville, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Register for Updates
Phase 1b Combo w/ Ribociclib and Alpelisib
NCT05508906
Recruiting
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Henry-Joyce Cancer Clinic, The Vanderbilt Clinic, Nashville, Tennessee
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542
Recruiting
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609
Recruiting
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 thera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/28/2023
Locations: Ascendis Pharma Investigational Site, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer
Register for Updates
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Tennessee Oncology, Nashville, Tennessee +1 locations
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Register for Updates